期刊
RADIOTHERAPY AND ONCOLOGY
卷 108, 期 1, 页码 40-47出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2013.05.017
关键词
Bladder cancer; Hypoxic modification; Necrosis; Biomarker; Radiotherapy; Carbogen and nicotinamide
资金
- Cancer Research UK [C1094/A11365]
- Medical Research Council of UK [G0801525]
- Experimental Cancer Medicine Centre
- Medical Research Council [G0801525] Funding Source: researchfish
- MRC [G0801525] Funding Source: UKRI
Background and purpose: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification. Materials and methods: Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and nicotinamide (RT + CON). Histopathological tumour features examined were: necrosis, growth pattern, growing margin, and tumour/stroma ratio. Hypoxia markers carbonic anhydrase-IX and glucose transporter-1 were examined using tissue microarrays. Results: Necrosis was the only independent prognostic indicator (P = 0.04). Necrosis also predicted benefit from hypoxia modification. Five-year overall survival was 48% (RT) versus 39% (RT + CON) (P = 0.32) in patients without necrosis and 34% (RT) versus 56% (RT + CON) (P = 0.004) in patients with necrosis. There was a significant treatment by necrosis strata interaction (P = 0.001 adjusted). Necrosis was an independent predictor of benefit from RT + CON versus RT (hazard ratio [HR]: 0.43, 95% CI 0.25-0.73, P = 0.002). This trend was not observed when there was no necrosis (HR: 1.64,95% CI 0.95-2.85, P = 0.08). Conclusions: Necrosis predicts benefit from hypoxia modification in patients with high risk bladder cancer and should be used to select patients; it is simple to identify and easy to incorporate into routine histopathological examination. (C) 2013 The Authors. Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据